ESR1 and cancer: They are less aggressive with better prognosis compared to hormone receptor negative BCs, which include the Her2 BC (Her2+, ER–, and PR–, designated herein as HR), and triple-negative (TN) cancer, which are ER, PR, and Her2 negative [9, 14].